AbbVie's Emrelis Receives Regulatory Approval in Brazil
1 report, 1 independent
Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Brazil's regulator Anvisa approved AbbVie's Emrelis for the treatment of non-squamous non-small cell lung cancer. The registration was granted on October 16 and is valid until October 2029. Emrelis is indicated for adults who have already received treatment and whose tumors show high levels of the c-Met protein.
From riotimesonline.com
Why it matters
The approval expands market access for AbbVie's cancer treatment in Brazil, following its accelerated approval in the United States in May 2025. The drug's approval is based on a Phase 2 study where 34.5% of patients saw tumors shrink.
From riotimesonline.com
Who's involved
- AbbVieManufacturer of the approved drug Emrelis